{"nctId":"NCT00106691","briefTitle":"Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)","startDateStruct":{"date":"2005-01"},"conditions":["Preneoplastic Conditions","Prostatic Intraepithelial Neoplasia"],"count":1589,"armGroups":[{"label":"20 mg Toremifene Citrate","type":"EXPERIMENTAL","interventionNames":["Drug: Toremifene 20 mg"]},{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Toremifene 20 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Give voluntary signed informed consent in accordance with institutional policies\n* Be male, aged ≥ 30 years\n* Have a diagnosis of high grade PIN from any previous prostate biopsy. The diagnosis of high grade PIN must be confirmed by the central pathologist\n* Have had a prostate biopsy in the last 6 months with a minimum of 10 cores that shows no evidence of cancer as confirmed by the central pathologist; OR, have had 2 prostate biopsies (each with a minimum of 6 cores) in the 12 months prior to screening with at least one of the biopsies occurring within 6 months prior to the screening visit. Both biopsies should have no evidence of cancer as confirmed by the central pathologist\n* Have a serum PSA of ≤ 10 ng/mL\n* Agree to provide tablet containers for tablet counts and to complete a daily diary of study drug intake\n* Agree to use an effective method of contraception, if the partner is of child-bearing age, while on study and for 30 days after the last dose of study medication\n* Have adequate bone marrow, liver and renal function:\n\n  * White Blood Cell (WBC) Count ≥ 3,000/mm3;\n  * Platelet Count ≥ 100,000/mm3;\n  * Bilirubin ≤ 1.5 mg/dL;\n  * AST and ALT \\< 2x upper limit of normal;\n  * Serum Creatinine ≤ 2.0 mg%\n\nExclusion Criteria:\n\n* Previous exposure to toremifene citrate\n* Have evidence of prostate cancer (local, regional and/or distal metastasis)\n* Have any history of other malignancies (Exceptions include non-melanoma skin cancer or other cancer that has no evidence of tumor reoccurrence 5 years after definitive treatment).\n* Have active systemic viral, bacterial, or fungal infections requiring treatment\n* Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol\n* Concurrently being treated with other investigational agents or have participated in an investigational study within 60 days prior to screening\n* Currently taking dutasteride. Subject is eligible if he stops dutasteride for a total washout of 90 days prior to the Screening Visit and agrees not to use dutasteride for the duration of the study.\n* Have previously taken finasteride for greater than two years\n* Currently taking finasteride. Subject is eligible if he stops finasteride for a total washout of 30 days prior to the Screening Visit and agrees not to use finasteride for the duration of the study.\n* Currently taking testosterone or testosterone-like supplements, such as dehydroepiandrosterone (DHEA). Subject is eligible if he stops these agents for a total washout of 30 days prior to the Screening Visit and agrees not to use these agents for the duration of the study.\n* Have a history of taking PC-SPES within the past two years.\n* Currently taking herbal medicine or dietary supplements for prostate health, such as Saw Palmetto (also known as Serenoa Repens).\n\nSubject is eligible if he stops these agents for a total washout of 30 days prior to taking the first dose of study drug and agrees not to use these agents for the duration of the study.\n\nLycopene, vitamin E and selenium are not prohibited and no washout is required. However, vitamin E intake should be limited to less than 400 i.u. per day.\n\n* Have a history of thromboembolic event or disease including deep vein thrombosis, pulmonary embolus, or thrombotic stroke\n* History of chronic hepatitis or cirrhosis","healthyVolunteers":false,"sex":"MALE","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)","description":"To measure the efficacy of toremifene citrate in men with high grade prostatic intraepithelial neoplasia (PIN). Prostate cancer-free survival distributions (Kaplan-Meier)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":"36.0"},{"groupId":"OG001","value":"59.5","spread":"36.0"}]}]}]},{"type":"SECONDARY","title":"The Effect of Toremifene on Lipid Levels","description":"Measure lipid levels including total cholesterol, LDL, HDL and Triglycerides % change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.678","spread":"18.2317"},{"groupId":"OG001","value":"-6.675","spread":"116.9705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.447","spread":"64.8765"},{"groupId":"OG001","value":"-7.824","spread":"28.8209"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"19.133"},{"groupId":"OG001","value":"0.29","spread":"16.650"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.298","spread":"58.003"},{"groupId":"OG001","value":"0.319","spread":"47.9793"}]}]}]},{"type":"SECONDARY","title":"The Effect of Toremifene on Hormone Levels","description":"% Change from baseline hormone levels, including total testosterone, free testosterone, dihydrotestosterone (DHT) and estradiol","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.736","spread":"48.3284"},{"groupId":"OG001","value":"46.409","spread":"60.2061"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"67.86"},{"groupId":"OG001","value":"53.2","spread":"151.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.246","spread":"102.9086"},{"groupId":"OG001","value":"31.136","spread":"63.5961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.71","spread":"438.652"},{"groupId":"OG001","value":"7.92","spread":"65.114"}]}]}]},{"type":"SECONDARY","title":"The Effect of Toremifene on Total PSA (Prostate Specific Antigen) Levels","description":"To assess the effect of toremifene in the total PSA (prostate specific antigen) levels from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"7.360"},{"groupId":"OG001","value":"1.07","spread":"3.632"}]}]}]},{"type":"SECONDARY","title":"The Effect of Toremifene on the Mean Change at 36 Months in AUA (American Urological Association) Symptom Score","description":"To assess the effect of toremifene on the AUA (American Urological Association) symptom score mean change from baseline. Scores of 0-7=mild severity, 8-9, moderate, and 20-30, severe with possible responses of 0 (not at all) 1 (\\<1/5), 2 (\\<50% time), 3 (about 50% time), 4 (\\> 50% time) \\& 5 (Almost Always). There are 7 questions (1)Incomplete emptying (2)Frequency (3)Intermittency (4)Urgency (5)Weak-stream (6)Straining \\& (7)Nocturia. Analysis is change from baseline at final evaluation (36 months) for quality of life due to urinary symptoms. The P Value is from a Wilcoxon signed-rank test. Scores can range from 0-35, highest representing worse symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"5.4"},{"groupId":"OG001","value":"1.2","spread":"5.6"}]}]}]},{"type":"PRIMARY","title":"Occurrence of a Positive Cancer Biopsy","description":"To measure the occurrence of a positive cancer biopsy","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of High Grade PIN at the 12, 24, 36 Month Biopsies","description":"To measure the occurrence of high grade PIN at the 12, 24, 36 Month intervals in the 360 days study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"The Effect of Toremifene on % Free Serum PSA (Prostate Specific Antigen) Levels, Change From Baseline","description":"To assess the effect of toremifene in % free serum PSA (prostate specific antigen) levels, change from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"11.24"},{"groupId":"OG001","value":"2.0","spread":"10.49"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":137,"n":802},"commonTop":["Hypertension","Arthralgia","Urinary tract infection","Upper respiratory tract infection","Prostatitis"]}}}